PDB16 First Results of the Post-Marketing Survey of Vildagliptin in France  by Attali, C. et al.
baseline and 3 months in 344/383 patients who took1 dose of study drug. Patients
were obese (mean [ SD] BMI  32.3 [ 7.7] kg/m2) and 80% had T2DM. Mean
HbA1c was 9.1% ( 1.5) at baseline and 8.3% ( 1.2) after 3 months; 11.6% reached
HbA1c7%. The mealtime insulin dose at 3 months was 38.6 IU ( 28.0). A cluster of
4 factors that favourably affected glycaemic control was identified: T2DM, lower
baseline HbA1c1 hypoglycaemic event, and being Caucasian. Patients with T1DM
and those taking at least one cardiovascular medication were less likely to reach
target. Comparing the overall p-values for the crude and adjusted odds ratios sug-
gested that HbA1c at baseline, type of diabetes and higher number of hypoglycae-
mic events were interrelated, while racial group was independent of the other
factors. CONCLUSIONS: Patients who achieved HbA1c 7.0% 3 months after the
addition of insulin glulisine were likely to have T2DM, a lower baseline HbA1c, more
hypoglycaemic episodes and be Caucasian.
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OBJECTIVES: To assess the clinical and economic benefits associated with ade-
quate and early insulin initiation and intensification in people with T2DM.
METHODS: A systematic review was performed using published papers from Jan-
uary 2000 to August 2010 that assessed intervention, disease, study design and
outcomes. Studies were classified as initiation and intensification based on pre-
defined criteria. Individual studies from systematic reviews and meta-analysis
identified in our review were searched and included if relevant. RESULTS: We
screened 2690 articles, of which 76 (40 initiation and 36 intensification) studies
were included. Baseline HbA1c values were in all initiation studies8.5%. Endpoint
HbA1c values were reduced with insulin in all studies, with endpoint values rang-
ing from 6.6% to 9.8%. Similar baseline and endpoint HbA1c were seen with the
intensification studies (endpoint HbA1c ranging from 6.4% to 9.6%). Addition of
insulin to oral anti-diabetic agents (OADs) resulted in better glycaemic control in
most studies. Blood glucose levels reduced substantially with OADsinsulin com-
pared to OADs alone. Quality of life outcomes and treatment satisfaction were
reported in six studies and not significantly different for insulin versus OADs.
Hypoglycaemic events were lower with insulin initiation versus OADs (1.391.16
vs. 2.301.87; 9/27 vs. 17/28). However, all insulin types were associated with
weight gain though the comparison with OADs elicited varying results. Economic
outcomes were reported in four studies with insulin initiation. Some studies reported
a reduced incidence in diabetes-related complications with insulin, resulting in lower
diabetes-related medical and total healthcare costs in these patients. Two studies
showed that initiating insulin in those failing OADs resulted in increase in life expec-
tancy and quality-adjusted life expectancy. CONCLUSIONS: Proactive management
of uncontrolled glycaemia in people with T2DM should be considered with early
insulin initiation and intensification. Further studies are required to explore the
economic benefits with early insulin initiation and intensification.
PDB15
USE OF HYPOGLICEMIC DRUGS IN SERBIA: PHARMACOTHERAPEUTIC VERSUS
PHARMACOECONOMIC ASPECTS
Sabo A, Tomic Z
Medical faculty Novi Sad Serbia, Novi Sad, Serbia and Montenegro
OBJECTIVES: To analyse the use of hypoglycemic drugs in Serbia from pharmaco-
therapeutic and pharmacoeconomic point. To see the influence of pharmacother-
apeutic guidelines and cost on use of hipoglicemic drugs when compared with the
countries with developed pharmacotherapy. METHODS: Use of hypoglicemic
drugs in Serbia was obtained from National Agency for drugs in Serbia (ALIMS). The
costs of hypoglycemic drugs was obtained from Serbian reimbursment company.
The use of drugs was expressed in DDD/1000 inh/day, and compared to the price of
drugs in the cathegory. RESULTS: The total use of hypoglycemic drugs in Serbia (56
DDD/1000inh/day) was similar to the use of drugs in this cathegory in another
countries. Use of insulins was lower in Serbia, probably because slightly different
pharmacotherapeutic approach to DM Typ II in Serbia. The structure of oral hypo-
glycemics was similar in Serbia and in comparator countries (Norway, Finland).
While metformin was the most often used hypoglicemic drug in countries with
developed pharmacotherapy, in Serbia the most often used drugs were sulfonyl-
urea drugs, with glibenclamide and gliclaside being in the first place. Gliclaside,
being on the second place in Serbia, is the most expensive hypoglicemic drug (price
per DDD 12.15 Serbian dinars). If gliclaside would be changed with another, less
expensive drug, the national reimbursment company would spare significant
amount of money. Glimepiride, the most often used and the cheaper sulfonylurea
derivative in countries with developed phrmacotherapy, was on the third place in
Serbia. CONCLUSIONS: The total use of hypoglycemics in Serbia is comparable to
countries with developed pharmacotherapy, indicating the satisfiing level of the
treatment of diabetes mellitus. However, the structure og hypoglycemics used is
suboptimal from pharmacotherapeutic and from pharmacoeconomic point of
wiev. Significant improvement are needed, which would improve pharmacother-
apy and pharmacoeconomic aspect of use of this drugs.
PDB16
FIRST RESULTS OF THE POST-MARKETING SURVEY OF VILDAGLIPTIN IN
FRANCE
Attali C1, Bringer J2, Simon D3, Eschwège E4, Deschaseaux C5, Dejager S5, Quere S5,
Bouee S6, Detournay B6
1Cabinet Médical de Groupe, Epinay sous sénart, France, 2CHRU Montpellier, Montpellier, France,
3Hôpital de la Pitié, Paris, France, 4INSERM, Villejuif, France, 5Novartis Pharma, Rueil
Malmaison, France, 6Cemka, Bourg la Reine, France
OBJECTIVES: To assess the characteristics of type 2 diabetes patients treated with
vildagliptin (a new DPP-4 inhibitor) and to evaluate potential misuse, treatment
adherence, effectiveness and tolerability of vildagliptin under real-life conditions
of care in France.METHODS: Following a request by the French Health Technology
Agency (Haute Autorité de Santé) an observational cohort study was started in
2010. The study population included a representative sample of patients with type
2 diabetes initiating a treatment with vildagliptin. Patients were enrolled through a
national sample of vildagliptin prescribers Data collected included sociodemo-
graphic characteristics, clinical history, comorbidities, detailed treatment and lab-
oratory data, physical exam and adherence. RESULTS: Overall, 482 GPs and 84
endocrinologists enrolled 1702 patients. Sixty percent were males, mean age was
63 (11) years, mean disease duration was 7 (6.5) years and mean HbA1C 7.8%
(1.2). Forty-five percent were obese and 39% overweight, 70% were treated for
hypertension and 66% for dyslipidaemia, and 1256 patients (74%) were treated with
vildagliptin/metformin fixed combination (Eucreas, FC) and 442 (26%) with vilda-
gliptin (Galvus). Main reasons for initiating vildagliptin were: previous treatment
failure (82%), weight gain (17%), reducing the numbers of pills (16%) and intolerance
to a previous treatment (12%). In accordance to the precautions of use, 1366 pa-
tients (80%) underwent liver function tests, and 1552 patients (91%) blood creati-
nine measurement prior to treatment initiation. In few cases, vildagliptin was
prescribed to patients for whom the product was not recommended: at baseline,
2.1% of treated patients presented elevations in alanine/aspartate aminotransfer-
ase  3 times the upper limit of normal, 0.3% a NYHA class III congestive heart
failure (no class IV) and 9.3% did not respect the precautions of use for renal
function. CONCLUSIONS: Most prescriptions of vildagliptin were in accordance
with the summary of product characteristics in this large, randomly selected
French population.
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OBJECTIVES: Off-label is defined by the Turkish Ministry of Health (MoHT) as the
use of licensed pharmaceutical products in doses outside of or exceeding the scope
of the registered indication, and the use of non-licensed but imported medicinal
products for the purpose of individual treatment. The use of off-label or non-
licensed endocrinology medicines were evaluated in order to provide an under-
standing of Turkey’s perspective within this area of healthcare provisions.
METHODS: A computer search was performed of IEGM’s database. A patient base
using off-label endocrinology medicine applications from 19 June 2009 to 19 June
2010 were searched. RESULTS: The computer search for the showed that 357 ap-
plications were submitted for off-label endocrinology medicine use. It was con-
cluded that the highest application percentage was established by “osteoporosis”
in all of the applications (43%, 155/357). The highest application was established by
Ankara province (28%, 44/155). University hospitals had the highest off-label osteo-
porosis medicine use applications within the given timeline (65%, 102/155). Spe-
cialized physicians in the fields of endocrinology and metabolism (adult and pae-
diatric) had the highest number of off-label osteoporosis applications (71%, 111/
155). It was concluded that the highest application percentage was established by
“teriparatide use in osteoporosis” (87%, 136/155) in all of the osteoporosis applica-
tions. 92 of 136 applications were approved. There was a significiant difference
between the T score (L1-4) of rejected and approved applications for patients
(3.071,85 and 3.231.63, respectively) (p0.001). Yet there was not a significiant
difference between ages of patients for whom applications were rejected or
approved. CONCLUSIONS: It could be said that off-label use can lead to reimburse-
ment restrictions in endocrinology, especially for teriparatide-like oncology med-
icines. In Turkey, physicians who want to prescribe an off-label or non-licensed
pharmaceutical or a medicine which has a different use from reimbursement in-
dications, need to apply through the off-label medicine use process.
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OBJECTIVES: Xerosis is a common disorder among diabetic patients; 82.1% of dia-
betic patients suffer from xerosis, which may or may not be combined with fissures
or cracking. It causes disorders which play a major role in the onset of ulceration.
Xerosis exacerbates the development and the recurrence, in particular, of hyper-
keratosis. To evaluate, under real use conditions, the effect of Pedimed (Glycerine,
petroleum jelly, piroctone olamine, tocopheryl nicotinate, hydroalcoholic ruscus
extr) on diabetic foot. METHODS: Observation study of diabetic patients with high
risk factor for foot ulceration in Australian centres, with data collected via ques-
tionnaires from patients receiving PediMed® to measure acceptability and xerosis
assessment from physicians and healthcare professionals. RESULTS: Mean age of
subjects is 57 years ( 13.3), 64% presenting with type 2 diabetes. The XAS score
measured by the doctor at inclusion is 6.4 ( 2.4) and 6.3 ( 2.6), respectively for the
right and left foot. At 4 weeks, measured by the same doctor, the XAS score is 2.7 (
2.3) and 3.0 ( 2.3) respectively for the right and left foot. Improvements are statis-
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